Navigation Links
Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads
Date:9/22/2010

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads

 

BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ -- Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST. Magnetic cell separation with MACS(R) Technology is the method of choice for the specific isolation of viable cells. A prerequisite for specific cell isolation is the availability of antibodies directed against a specific cell surface antigen. Suitable antibodies against extracellular markers on the astrocyte cell surface were not available until recently, and astrocytes had to be isolated by time-consuming methods, such as generation of astrocyte cultures, which even differ considerably from astrocytes in vivo, or by transgenic approaches.

The new anti-GLAST (ACSA-1) antibody (astrocyte cell surface antigen 1; ACSA-1) recognizes an extracellular epitope of the astrocyte-specific glutamate transporter GLAST (EAAT1), and it shows specific and sensitive labeling of GLAST-positive cells in flow cytometry, immunohistochemistry, and immunocytochemistry.

"The Anti-GLAST (ACSA-1) MicroBead Kit provides the first tool for the straightforward isolation of astrocytes from dissociated brain tissue, and enables the separation of astrocytes based on their expression of GLAST," says Dr. Melanie Jungblut, the responsible R&D Project Manager. "The kit allows for the direct isolation of viable primary astrocytes within one hour, and achieves high purity by minimizing contamination by other cells."

The Anti-GLAST (ACSA-1) MicroBead Kit is exclusively available from Miltenyi Biotec.

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. More than 1,100 employees worldwide develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

Press contact: Prof. Dr. Uwe A. O. Heinlein Corporate Communications, Miltenyi Biotec GmbH Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany Phone: +49-2204-8306-6590 E-mail: uweh@miltenyibiotec.de .
'/>"/>

SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
2. Directors Forum: PEPFAR and the Global AIDS Response
3. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
4. West Pharmaceutical Services, Inc. Appoints New Director
5. Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
10. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):